Brief: VYNE Therapeutics Announces Positive Data From Phase 1a Trial For VYN201

YARROW BIOSCIENCE

30/03/2023 12:50

March 30 (Reuters) - VYNE Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN
PHARMACOKINETIC AND HEMATOLOGY DATA FROM PHASE 1A SINGLE AND
MULTIPLE ASCENDING DOSE TRIAL FOR NOVEL PAN-BROMODOMAIN BET
INHIBITOR VYN201
    * VYNE THERAPEUTICS INC - TOPLINE PHASE 1B RESULTS IN
PATIENTS
WITH NONSEGMENTAL VITILIGO EXPECTED IN MID-2023
    * VYNE THERAPEUTICS INC - ALL HEMATOLOGICAL PARAMETERS,
INCLUDING
PLATELET COUNTS, WERE WITHIN NORMAL RANGES
    * VYNE THERAPEUTICS INC - RESULTS HAVE SHOWN THAT THERE WERE
NO
QUANTIFIABLE VYN201 PLASMA CONCENTRATIONS ABOVE ASSAY LOWER
LIMIT OF QUANTIFICATION
    * VYNE THERAPEUTICS INC - ENROLLMENT IN PHASE 1B PORTION OF
TRIAL
IS ONGOING

Source text for Eikon:  ID:nGNX4DNmRK 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))